Last reviewed · How we verify
Iodixanol(Drug)
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and body cavities by absorbing X-rays.
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and body cavities by absorbing X-rays. Used for Coronary angiography and left ventriculography, Peripheral arteriography, Renal arteriography.
At a glance
| Generic name | Iodixanol(Drug) |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Iso-osmolar contrast medium (IOCM) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iodixanol contains iodine atoms that attenuate X-ray radiation, creating contrast in radiographic imaging. As an iso-osmolar contrast medium (IOCM), it has an osmolality equal to blood plasma, which may reduce nephrotoxicity and adverse reactions compared to hyperosmolar agents. It is used for angiographic and urographic procedures to visualize vascular and urinary anatomy.
Approved indications
- Coronary angiography and left ventriculography
- Peripheral arteriography
- Renal arteriography
- Excretory urography
- Computed tomography (CT) imaging
Common side effects
- Contrast-induced nephropathy (CIN)
- Allergic reaction
- Nausea and vomiting
- Flushing and warmth sensation
- Hypersensitivity reactions
Key clinical trials
- Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis (NA)
- Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma (NA)
- Intra-discal Steroid Injection for MODIC I Discopathy (PHASE4)
- Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material (PHASE4)
- Effect of Evolocumab on Coronary Atherosclerosis (PHASE3)
- Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes (PHASE1)
- Pediatric Risk of Hypothyroidism With Iodinated Contrast Media (PHASE4)
- Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iodixanol(Drug) CI brief — competitive landscape report
- Iodixanol(Drug) updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI